~~<i id='B4C8CFE527'><strike id='B4C8CFE527'><tt id='B4C8CFE527'><pre id='B4C8CFE527'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

knowledge

author：comprehensive 2025-09-27 23:32:39 - browse：517

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Primary care doctor shortage won't be solved by free med school tuition

entertainment

hotspot

Wikipedia

explore

AdobePresidentBidenorderedthenation’sleadinghealthagenciesonMondaytodevelopaplanforregulatingartific

WSS

Maker of FluMist seeks to allow at

Chimpanzees, like humans and whales, get menopause: Study

As health system earnings go up, health insurance stocks go down

Traditional Chinese medicine benefits explored in new JAMA study

CDC recommends rationing of RSV shot due to shortages

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

explore

knowledge

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

The FDA weighs the risks of candy

Walensky prepares to leave CDC — and Congress — behind

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Apple is now the first public company to be valued at $3 trillion

Senate panel to vote on hospitals, PBMs, prisoner care

Hollywood unions extend contract negotiations for actors

BIO to announce reorganization, senior leaders expected to depart

Anesthesiologist group: stop taking Ozempic before surgery

Emergency medicine has repudiated 'excited delirium.' Now what?

hotspot

Paying for Covid pills will soon shift to insurers

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Maker of FluMist seeks to allow at

Chemotherapy before breast cancer surgery might fuel metastasis

WHO may add ‘noma' to its list of neglected tropical diseases

AI for drug discovery: Experts on separating hype from reality

Wikipedia

explore

explore

explore